Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Abstract P4-01-26: The Xpert® Breast Cancer Insight test predicts distant recurrence and overall survival in estrogen receptor-positive, HER2-negative early breast cancer: A validation study in ABCSG Trial 8

Clin Cancer Res (2025) 31 (12_Supplement): P4-01-26.

https://doi.org/10.1158/1557-3265.SABCS24-P4-01-26

Published: 13 June 2025

View articletitled, Abstract P4-01-26: The Xpert® Breast Cancer Insight test predicts distant recurrence and overall survival in estrogen receptor-positive, HER2-negative early breast cancer: A validation study in ABCSG Trial 8

Journal Articles

Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial

Christian F. Singer, Dominik Hlauschek, Georg Pfeiler, Daniel Egle, Rupert Bartsch, Christoph Suppan, Angelika Pichler, Edgar Petru, Richard Greil, Margaretha Rudas, Michael Seifert, Gregor Huber, Andreas Petzer, Florian Fitzal, Zsuzsanna Bago-Horvath, Martin Filipits, Lidija Soelkner, Christian Fesl, Michael Gnant

Clin Cancer Res (2025) 31 (12_Supplement): PS3-03.

https://doi.org/10.1158/1557-3265.SABCS24-PS3-03

Published: 13 June 2025

View articletitled, Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial

Journal Articles

Abstract P2-03-30: Association of ctDNA in patients with long-term outcome of breast cancer patients undergoing neoadjuvant treatment in the randomized ABCSG 34 clinical trial

Clin Cancer Res (2025) 31 (12_Supplement): P2-03-30.

https://doi.org/10.1158/1557-3265.SABCS24-P2-03-30

Published: 13 June 2025

View articletitled, Abstract P2-03-30: Association of ctDNA in patients with long-term outcome of breast cancer patients undergoing neoadjuvant treatment in the randomized ABCSG 34 clinical trial

Journal Articles

Abstract P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trial

Ulrike M. Heber, Dominik Hlauschek, Christian F. Singer, Daniel Egle, Richard Greil, Ruth Helfgott, Gregor Huber, Elisabeth Müller-Holzner, Cornelia Hauser-Kronberger, Margaretha Rudas, Georg Pfeiler, Rupert Bartsch, Sigurd Lax, Martin Filipits, Gabriel Rinnerthaler, Michael Gnant, Zsuzsanna Bago-Horvath

Clin Cancer Res (2025) 31 (12_Supplement): P2-01-24.

https://doi.org/10.1158/1557-3265.SABCS24-P2-01-24

Published: 13 June 2025

View articletitled, Abstract P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trial

Journal Articles

Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer:

Clin Cancer Res (2025) 31 (12_Supplement): GS1-09.

https://doi.org/10.1158/1557-3265.SABCS24-GS1-09

Published: 13 June 2025

View articletitled, Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer:

Journal Articles

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer

Christian F. Singer, for the ABCSG, Frederik Holst, Stefan Steurer, Eike C. Burandt, Sigurd F. Lax, Raimund Jakesz, Margaretha Rudas, Herbert Stöger, Richard Greil, for the ABCSG, Guido Sauter, Martin Filipits, for the ABCSG, Ronald Simon, Michael Gnant, for the ABCSG

Clin Cancer Res (2022) 28 (18): 4112–4120.

https://doi.org/10.1158/1078-0432.CCR-21-4328

Published: 15 September 2022

View articletitled, Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer

Journal Articles

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

Clin Cancer Res (2022) 28 (4): 697–707.

https://doi.org/10.1158/1078-0432.CCR-21-3231

Published: 15 February 2022

View articletitled, Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

Includes: Supplementary data

Journal Articles

The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

Martin Filipits, Margaretha Rudas, Verena Kainz, Christian F. Singer, Florian Fitzal, Zsuzsanna Bago-Horvath, Richard Greil, Marija Balic, Peter Regitnig, Stefan Halper, Wolfgang Hulla, Daniel Egle, Stephen Barron, Tony Loughman, Des O'Leary, William M. Gallagher, Dominik Hlauschek, Michael Gnant, Peter Dubsky

Clin Cancer Res (2021) 27 (21): 5931–5938.

https://doi.org/10.1158/1078-0432.CCR-21-1023

Published: 01 November 2021

View articletitled, The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

Includes: Supplementary data

Journal Articles

Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5

Zsuzsanna Bago-Horvath, Margaretha Rudas, Christian F. Singer, Richard Greil, Marija Balic, Sigurd F. Lax, Werner Kwasny, Wolfgang Hulla, Michael Gnant, Martin Filipits

Clin Cancer Res (2020) 26 (21): 5682–5688.

https://doi.org/10.1158/1078-0432.CCR-20-0673

Published: 02 November 2020

View articletitled, Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5

Journal Articles

Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer

Ivana Sestak, Martin Filipits, Richard Buus, Margaretha Rudas, Marija Balic, Michael Knauer, Ralf Kronenwett, Florian Fitzal, Jack Cuzick, Michael Gnant, Richard Greil, Mitch Dowsett, Peter Dubsky

Clin Cancer Res (2020) 26 (17): 4682–4687.

https://doi.org/10.1158/1078-0432.CCR-20-0260

Published: 01 September 2020

View articletitled, Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer

Journal Articles

Prediction of Distant Recurrence Using EndoPredict Among Women with ER⁺, HER2⁻ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

Martin Filipits, Peter Dubsky, Margaretha Rudas, Richard Greil, Marija Balic, Zsuzsanna Bago-Horvath, Christian F. Singer, Dominik Hlauschek, Krystal Brown, Ryan Bernhisel, Ralf Kronenwett, Johnathan M. Lancaster, Florian Fitzal, Michael Gnant

Clin Cancer Res (2019) 25 (13): 3865–3872.

https://doi.org/10.1158/1078-0432.CCR-19-0376

Published: 01 July 2019

View articletitled, Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

Includes: Supplementary data

Journal Articles

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Clin Cancer Res (2019) 25 (10): 2975–2987.

https://doi.org/10.1158/1078-0432.CCR-18-3160

Published: 15 May 2019

View articletitled, A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Includes: Supplementary data

Journal Articles

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases

Elisabeth S. Bergen, Anna S. Berghoff, Mela Medjedovic, Margaretha Rudas, Florian Fitzal, Zsuzsanna Bago-Horvath, Karin Dieckmann, Robert M. Mader, Ruth Exner, Michael Gnant, Christoph C. Zielinski, Guenther G. Steger, Matthias Preusser, Rupert Bartsch

Clin Cancer Res (2019) 25 (9): 2737–2744.

https://doi.org/10.1158/1078-0432.CCR-18-1968

Published: 01 May 2019

View articletitled, Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases

Includes: Supplementary data

Journal Articles

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Martin Filipits, Urania Dafni, Michael Gnant, Varvara Polydoropoulou, Margaret Hills, Astrid Kiermaier, Evandro de Azambuja, Denis Larsimont, Federico Rojo, Giuseppe Viale, Masakazu Toi, Nadia Harbeck, Kathleen I. Prichard, Richard D. Gelber, Phuong Dinh, Dimitrios Zardavas, Brian Leyland-Jones, Martine J. Piccart-Gebhart, Mitch Dowsett

Clin Cancer Res (2018) 24 (13): 3079–3086.

https://doi.org/10.1158/1078-0432.CCR-17-3473

Published: 01 July 2018

View articletitled, Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Includes: Supplementary data

Journal Articles

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Christian F. Singer, Yen Y. Tan, Florian Fitzal, Guenther G. Steger, Daniel Egle, Angelika Reiner, Margaretha Rudas, Farid Moinfar, Christine Gruber, Edgar Petru, Rupert Bartsch, Kristina A. Tendl, David Fuchs, Michael Seifert, Ruth Exner, Marija Balic, Zsuzsanna Bago-Horvath, Martin Filipits, Michael Gnant

Clin Cancer Res (2017) 23 (14): 3676–3683.

https://doi.org/10.1158/1078-0432.CCR-16-2373

Published: 13 July 2017

View articletitled, Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract B28: Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer.

Anna Bachmayr-Heyda, Stefanie Aust, Katharina Auer, Peter Borossay, Nina Pecha, Ugo Cavallaro, Ioana Braicu, Sarah Igidbashian, Costanza Savino, Franchi Dorella, Jalid Sehouli, Sonia Zaafrani, Florian Fitzal, Christian Singer, Michael Gnant, Robert Zeillinger, Dietmar Pils

Clin Cancer Res (2016) 22 (2_Supplement): B28.

https://doi.org/10.1158/1557-3265.OVCA15-B28

Published: 15 January 2016

View articletitled, Abstract B28: Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer.

Journal Articles

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Clin Cancer Res (2014) 20 (5): 1298–1305.

https://doi.org/10.1158/1078-0432.CCR-13-1845

Published: 02 March 2014

View articletitled, The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

Includes: Supplementary data

Journal Articles

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Matthew P. Goetz, Vera J. Suman, Tanya L. Hoskin, Michael Gnant, Martin Filipits, Stephanie L. Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil, Otto Dietze, Alois Lang, Felix Offner, Carol A. Reynolds, Richard M. Weinshilboum, Matthew M. Ames, James N. Ingle

Clin Cancer Res (2013) 19 (2): 500–507.

https://doi.org/10.1158/1078-0432.CCR-12-2153

Published: 16 January 2013

View articletitled, CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Journal Articles

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Zsuzsanna Bago-Horvath, Margaretha Rudas, Peter Dubsky, Raimund Jakesz, Christian F. Singer, Ralf Kemmerling, Richard Greil, Andrea Jelen, Gerhard Böhm, Zerina Jasarevic, Anton Haid, Christine Gruber, Sabine Pöstlberger, Martin Filipits, Michael Gnant

Clin Cancer Res (2011) 17 (24): 7828–7834.

https://doi.org/10.1158/1078-0432.CCR-11-1846

Published: 18 December 2011

View articletitled, Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

Journal Articles

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Clin Cancer Res (2011) 17 (18): 6012–6020.

https://doi.org/10.1158/1078-0432.CCR-11-0926

Published: 14 September 2011

View articletitled, A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Includes: Supplementary data

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract P4-01-26: The Xpert® Breast Cancer Insight test predicts distant recurrence and overall survival in estrogen receptor-positive, HER2-negative early breast cancer: A validation study in ABCSG Trial 8

Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial

Abstract P2-03-30: Association of ctDNA in patients with long-term outcome of breast cancer patients undergoing neoadjuvant treatment in the randomized ABCSG 34 clinical trial

Abstract P2-01-24: Immune activation of tumor cells and microenvironment as assessed by PD-L1 expression and interferon gamma signaling predict long term disease-free and overall survival: Results of the prospective randomized neoadjuvant ABCSG 34 trial

Abstract GS1-09: OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer:

Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response

The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8

Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the ABCSG Trial 5

Prognostic Value of EndoPredict in Women with Hormone Receptor–Positive, HER2-Negative Invasive Lobular Breast Cancer

Prediction of Distant Recurrence Using EndoPredict Among Women with ER⁺, HER2⁻ Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only

A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Abstract B28: Validation of a combined 13 gene six protein blood signature for earlier detection of ovarian cancer.

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Adjuvant Sequencing of Tamoxifen and Anastrozole Is Superior to Tamoxifen Alone in Postmenopausal Women with Low Proliferating Breast Cancer

A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only